FDA Handling Of Sanofi’s Ketek Is Latest Target Of Congressional Scrutiny
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Senate Finance Committee Chairman Chuck Grassley has requested that senior Center for Drug Evaluation & Research staff brief committee staff on FDA's regulatory oversight of Sanofi-Aventis' antibiotic Ketek by May 18